Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag FDA approves Yuvezzi, first fixed-dose eye drop for presbyopia, offering non-invasive vision improvement.

flag The FDA has approved Yuvezzi, a daily eye drop combining carbachol and brimonidine tartrate, as the first fixed-dose treatment for presbyopia, a common age-related near-vision loss affecting millions. flag The medication works by creating a pinhole effect through pupil constriction, improving both near and distance vision for up to 8 hours. flag Approval was based on two Phase 3 trials showing significant near vision improvement with no serious safety issues over 72,000 treatment days. flag Common side effects include headache, eye irritation, and temporary blurred vision. flag The drug, expected to launch in the second quarter of 2026, offers a non-invasive alternative to glasses or surgery.

7 Articles